WAYLAND, Mass.--(BUSINESS WIRE)--Candela Corporation (NASDAQ:CLZR), a global leader in aesthetic laser solutions, announced today that Candela lasers will be featured on The View this Friday morning, April 18. "The Body and the Beach" segment will feature Eric Bernstein, MD, from the Centers for Laser Surgery in Bryn Mawr, PA performing treatments combining the Serenity? Pro Pneumatic Skin Flattening Technology for increased patient comfort during GentleYAG? hair removal, and also demonstrating the use of the Vbeam? Perfecta pulsed dye laser for removal of spider veins on the legs.
Consumer beauty expert Marie Czenko Kuechel will be sharing with the ladies of The View, the "hottest" treatments to get a beach-ready body. The treatments with Candela lasers will showcase how quick, easy, and relatively pain-free aesthetic laser treatments can be as the summer season approaches.
To see where the program will air in your area, go to http://www.abcnews.com. To find a local practitioner that offers Serenity Pro hair removal treatments with the GentleYAG, or Vbeam leg vein treatments, visit http://www.candelalaser.com.
About CANDELA: Candela Corporation manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 70 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 19 years ago, and currently has an installed base of an estimated 12,000 lasers worldwide. Visit Candela on the Web at http://www.candelalaser.com.
Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. Such statements may relate to, among other things, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock. The risks and uncertainties that may affect forward-looking statements include, among others: the cancellation or deferral of customer orders, the risk of an adverse judgment in the patent litigation with Palomar Medical Technologies, Inc., the risk of an adverse judgment in the CardioFocus patent litigation, the risk of an adverse judgment in the securities class action lawsuit brought in early April, dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.
